DE502006009169D1 - NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID - Google Patents
NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMIDInfo
- Publication number
- DE502006009169D1 DE502006009169D1 DE502006009169T DE502006009169T DE502006009169D1 DE 502006009169 D1 DE502006009169 D1 DE 502006009169D1 DE 502006009169 T DE502006009169 T DE 502006009169T DE 502006009169 T DE502006009169 T DE 502006009169T DE 502006009169 D1 DE502006009169 D1 DE 502006009169D1
- Authority
- DE
- Germany
- Prior art keywords
- oxo
- oxazolidin
- morpholinyl
- methyl
- ylü
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005047564A DE102005047564A1 (de) | 2005-10-04 | 2005-10-04 | Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid |
DE102005047563A DE102005047563A1 (de) | 2005-10-04 | 2005-10-04 | Neue polymorphe Form von 5-Chlor-N-{(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid |
PCT/EP2006/009202 WO2007039132A1 (de) | 2005-10-04 | 2006-09-22 | Neue polymorphe form und die amorphe form von 5-chlor-n- ( { ( 5s ) -2-0x0-3-[4-( 3-oxo-4-morpholinyl) - phenyl] -1,3-oxazolidin-5-yl} -methyl) -2- thiophencarboxamid |
Publications (1)
Publication Number | Publication Date |
---|---|
DE502006009169D1 true DE502006009169D1 (en) | 2011-05-05 |
Family
ID=37691766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE502006009169T Active DE502006009169D1 (en) | 2005-10-04 | 2006-09-22 | NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID |
Country Status (23)
Country | Link |
---|---|
US (1) | US8188270B2 (de) |
EP (1) | EP1934208B1 (de) |
JP (1) | JP5416408B2 (de) |
KR (1) | KR101364400B1 (de) |
AT (1) | ATE502937T1 (de) |
AU (1) | AU2006299126B2 (de) |
BR (1) | BRPI0616801B8 (de) |
CA (2) | CA2624310C (de) |
CR (1) | CR9863A (de) |
DE (1) | DE502006009169D1 (de) |
DK (1) | DK1934208T3 (de) |
EC (1) | ECSP088341A (de) |
HK (1) | HK1125103A1 (de) |
IL (1) | IL190204A (de) |
MY (1) | MY145616A (de) |
NO (1) | NO341632B1 (de) |
NZ (1) | NZ567092A (de) |
PL (1) | PL1934208T3 (de) |
PT (1) | PT1934208E (de) |
RU (2) | RU2578602C2 (de) |
SG (1) | SG166126A1 (de) |
SV (1) | SV2009002858A (de) |
WO (1) | WO2007039132A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10129725A1 (de) | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10300111A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
EP1685841A1 (de) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prophylaxe und Behandlung von thrombolischen Erkrankungen |
DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
AU2006299126B2 (en) | 2005-10-04 | 2012-06-28 | Bayer Intellectual Property Gmbh | Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
DE102007028318A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Oxazolidinone zur Behandlung und Prophylaxe von Sepsis |
WO2009023233A1 (en) * | 2007-08-14 | 2009-02-19 | Concert Pharmaceuticals, Inc. | Substituted oxazolidinone derivatives |
EP2220079A2 (de) | 2007-11-15 | 2010-08-25 | Boehringer Ingelheim International GmbH | Substituierte amide sowie ihre herstellung und verwendung als medikamente |
DE102008028071A1 (de) * | 2008-06-12 | 2009-12-17 | Bayer Schering Pharma Aktiengesellschaft | Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure |
JP2011527297A (ja) | 2008-07-08 | 2011-10-27 | ラーツイオフアルム・ゲー・エム・ベー・ハー | 5−クロロ−n−({(5s)−2−オキソ−3−[4−(3−オキソ−4−モルホリニル)−フェニル]−1,3−オキサゾリジン−5−イル}−メチル)−2−チオフェンカルボキサミドを含む医薬組成物 |
US20100168111A1 (en) * | 2008-12-31 | 2010-07-01 | Apotex Pharmachem Inc. | Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide |
US7816355B1 (en) * | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
DK2442799T3 (da) | 2009-06-18 | 2017-01-02 | Krka Tovarna Zdravil D D Novo Mesto | Fast farmaceutisk sammensætning omfattende rivaroxaban |
EP2266541A1 (de) | 2009-06-18 | 2010-12-29 | Krka Tovarna Zdravil, D.D., Novo Mesto | Feste pharmazeutische Zusammensetzung mit Rivaroxaban |
EP2459555B1 (de) | 2009-07-31 | 2021-11-03 | KRKA, D.D., Novo Mesto | Verfahren zur kristallisierung von rivaroxaban |
EP2308472A1 (de) | 2009-10-06 | 2011-04-13 | ratiopharm GmbH | Pharmazeutische Zusammensetzungen, die Rivaroxaban umfassen |
WO2011042156A1 (en) | 2009-10-06 | 2011-04-14 | Ratiopharm Gmbh | Pharmaceutical compositions comprising rivaroxaban |
EP2404920A1 (de) | 2010-07-06 | 2012-01-11 | Sandoz AG | Kristalline Form von Rivaroxaban-Dihydrat |
US20130253187A1 (en) | 2010-09-14 | 2013-09-26 | Medichem, S.A. | Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative |
AT511045A1 (de) | 2011-01-28 | 2012-08-15 | Blum Gmbh Julius | Möbelteil mit einer drehmomentübertragenden welle |
US20140378682A1 (en) | 2011-09-08 | 2014-12-25 | Cadila Healthcare Limited | Processes and intermediates for preparing rivaroxaban |
EP2573084A1 (de) | 2011-09-22 | 2013-03-27 | Enantia, S.L. | Neue kristalline Formen von Rivaroxaban und Verfahren zur deren Herstellung |
HU230734B1 (hu) | 2011-10-10 | 2017-12-28 | EGIS Gyógyszergyár Nyrt | Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok |
WO2014016842A1 (en) * | 2012-07-23 | 2014-01-30 | Symed Labs Limited | Amorphous coprecipitates of rivaroxaban |
EP2935255B1 (de) | 2012-12-21 | 2017-08-16 | Farma GRS, d.o.o. | Verfahren zur herstellung von rivaroxaban |
EP2897619A4 (de) | 2012-12-26 | 2016-08-17 | Wanbury Ltd | Aldehydderivat aus substituierten oxazolidinonen |
WO2014102820A2 (en) | 2012-12-26 | 2014-07-03 | Wanbury Ltd. | Rivaroxaban intermediate and preparation thereof |
WO2015111076A2 (en) * | 2014-01-23 | 2015-07-30 | Symed Labs Limited | Improved processes for the preparation of highly pure rivaroxaban crystal modification i |
WO2015176677A1 (en) * | 2014-05-22 | 2015-11-26 | Sunshine Lake Pharma Co., Ltd. | Crystalline forms and amorphism of oxazolidinone compound |
EP3209661B1 (de) | 2014-10-22 | 2021-02-17 | Zaklady Farmaceutyczne Polpharma SA | Verfahren zur herstellung eines polymorphs von rivaroxaban |
RU2020103395A (ru) * | 2020-01-28 | 2021-07-28 | Закрытое Акционерное Общество "Алмаз Фарм" | L-, U-модификации 5-хлор-N-({ 5S)-2-оксо-3-[4-3-оксо-4-морфолинил)-фенил]-1,3-оксазолидин-5-ил} -метил)-2-тиофенкарбоксамида, сольват с диметилсульфоксидом, способы их получения, фармацевтические композиции на их основе, ингибирующие фактор Ха |
GB202102575D0 (en) | 2021-02-23 | 2021-04-07 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
GR1010231B (el) | 2021-03-24 | 2022-05-10 | Φαρματεν Α.Β.Ε.Ε., | Φαρμακευτικο σκευασμα που περιλαμβανει ριβαροξαμπανη και μεθοδος παρασκευης αυτου |
EP4201933A1 (de) | 2021-12-23 | 2023-06-28 | Zaklady Farmaceutyczne Polpharma S.A. | Kristallisationsverfahren für rivaroxaban |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2811555A (en) | 1955-05-02 | 1957-10-29 | Eastman Kodak Co | Reduction of 2-nitroso-5-diethylaminotoluene |
US3279880A (en) | 1965-07-12 | 1966-10-18 | Eastman Kodak Co | Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones |
LU80081A1 (fr) | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
US4128654A (en) | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4500519A (en) | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
HU190072B (en) | 1983-03-11 | 1986-08-28 | Biogal Gyogyszergyar,Hu | Process for production of medical preparatives with sinergetic influence |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
ES533097A0 (es) | 1983-06-07 | 1985-08-01 | Du Pont | Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno. |
US4977173A (en) | 1987-10-21 | 1990-12-11 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
ATE95176T1 (de) | 1987-10-21 | 1993-10-15 | Du Pont Merck Pharma | Aminomethyl-oxo-oxazolidinyl-ethenylbenzenderivate, nuetzlich als antibakterielles mittel. |
DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US5254577A (en) | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
KR100257418B1 (ko) | 1991-11-01 | 2000-05-15 | 로렌스 티. 마이젠헬더 | 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논 |
SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
US5349045A (en) | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
ES2134870T3 (es) | 1993-05-01 | 1999-10-16 | Merck Patent Gmbh | Antagonistas del receptor de adhesion. |
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
DE4332384A1 (de) | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
BR9607017A (pt) | 1995-02-03 | 1997-10-28 | Upjohn Co | Composto e uso do mesmo |
HRP960159A2 (en) | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
DE19524765A1 (de) | 1995-07-07 | 1997-01-09 | Boehringer Mannheim Gmbh | Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
BR9610474A (pt) | 1995-09-01 | 1999-03-02 | Upjohn Co | Feniloxazolidinonas tendo uma ligação c-c a anéis heterocíclicos com 4-8 membros |
JPH11512429A (ja) | 1995-09-15 | 1999-10-26 | ファルマシア・アンド・アップジョン・カンパニー | アミノアリールオキサゾリジノン n−オキシド |
DE19601264A1 (de) | 1996-01-16 | 1997-07-17 | Bayer Ag | Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone |
DE19604223A1 (de) | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
HRP970049A2 (en) | 1996-02-06 | 1998-04-30 | Bayer Ag | New heteroaryl oxazolidinones |
GB9614238D0 (en) | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
AU714618B2 (en) | 1996-07-15 | 2000-01-06 | Sankyo Company Limited | Medicinal composition |
US5935724A (en) | 1997-04-04 | 1999-08-10 | Wilson Greatbatch Ltd. | Electrochemical cell having multiplate electrodes with differing discharge rate regions |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
ES2242280T3 (es) | 1997-05-30 | 2005-11-01 | PHARMACIA & UPJOHN COMPANY LLC | Agentes antibacterianos de oxazolidinona que contienen funcionalidad tiocarbonilo. |
NZ502253A (en) | 1997-07-11 | 2001-06-29 | Upjohn Co | Thiadiazolyl and oxadiazolyl phenyl oxazolidinone derivatives which are antibacterial agents |
DE19730847A1 (de) | 1997-07-18 | 1999-01-28 | Bayer Ag | Tricyclisch substituierte Oxazolidinone |
GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
ATE250054T1 (de) | 1997-11-12 | 2003-10-15 | Upjohn Co | Oxazolidinone derivate und pharmazeutische zusammensetzungen |
US6083967A (en) | 1997-12-05 | 2000-07-04 | Pharmacia & Upjohn Company | S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones |
DE19755268A1 (de) | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
KR20010015910A (ko) | 1998-01-23 | 2001-02-26 | 로렌스 티. 마이젠헬더 | 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법 |
ZA99607B (en) | 1998-01-27 | 1999-07-27 | Rhone Poulenc Rorer Pharma | Substituted oxoazaheterocyclyl factor xa inhibitors. |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
EA003458B1 (ru) | 1998-05-18 | 2003-06-26 | Фармация Энд Апджон Компани | Усиление активности оксазолидиноновых антибактериальных агентов в результате применения производных аргинина |
DE19842753A1 (de) | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
PE20010851A1 (es) | 1999-12-14 | 2001-08-17 | Upjohn Co | Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina |
CA2389482A1 (en) | 1999-12-21 | 2001-06-28 | Jackson B. Hester, Jr. | Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
KR20020063609A (ko) * | 1999-12-28 | 2002-08-03 | 아지노모토 가부시키가이샤 | 아스파탐 유도체 결정 |
DE10105989A1 (de) | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10110438A1 (de) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115945A1 (de) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115922A1 (de) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10134481A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10152460A1 (de) | 2001-10-24 | 2003-05-08 | Bayer Ag | Stents |
DE10238113A1 (de) | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
US20040024660A1 (en) | 2002-08-05 | 2004-02-05 | General Electric Company | System and method for providing asset management and tracking capabilities |
DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
DE102004002044A1 (de) * | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (de) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prophylaxe und Behandlung von thrombolischen Erkrankungen |
DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
DE102005047558A1 (de) | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
AU2006299126B2 (en) | 2005-10-04 | 2012-06-28 | Bayer Intellectual Property Gmbh | Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
DE102005048824A1 (de) | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Behandlung und Prophylaxe von Mikroangiopathien |
-
2006
- 2006-09-22 AU AU2006299126A patent/AU2006299126B2/en active Active
- 2006-09-22 RU RU2011115874/04A patent/RU2578602C2/ru active
- 2006-09-22 DK DK06792210.4T patent/DK1934208T3/da active
- 2006-09-22 KR KR1020087008058A patent/KR101364400B1/ko active IP Right Grant
- 2006-09-22 RU RU2008116834/04A patent/RU2429236C2/ru active
- 2006-09-22 JP JP2008533895A patent/JP5416408B2/ja active Active
- 2006-09-22 PL PL06792210T patent/PL1934208T3/pl unknown
- 2006-09-22 NZ NZ567092A patent/NZ567092A/en unknown
- 2006-09-22 US US12/089,095 patent/US8188270B2/en active Active
- 2006-09-22 SG SG201007274-2A patent/SG166126A1/en unknown
- 2006-09-22 WO PCT/EP2006/009202 patent/WO2007039132A1/de active Application Filing
- 2006-09-22 MY MYPI20080967A patent/MY145616A/en unknown
- 2006-09-22 CA CA2624310A patent/CA2624310C/en active Active
- 2006-09-22 DE DE502006009169T patent/DE502006009169D1/de active Active
- 2006-09-22 BR BRPI0616801A patent/BRPI0616801B8/pt active IP Right Grant
- 2006-09-22 AT AT06792210T patent/ATE502937T1/de active
- 2006-09-22 EP EP06792210A patent/EP1934208B1/de active Active
- 2006-09-22 CA CA2823159A patent/CA2823159C/en active Active
- 2006-09-22 PT PT06792210T patent/PT1934208E/pt unknown
-
2008
- 2008-03-17 IL IL190204A patent/IL190204A/en active IP Right Grant
- 2008-04-02 SV SV2008002858A patent/SV2009002858A/es unknown
- 2008-04-02 EC EC2008008341A patent/ECSP088341A/es unknown
- 2008-04-03 CR CR9863A patent/CR9863A/es unknown
- 2008-04-30 NO NO20082059A patent/NO341632B1/no unknown
-
2009
- 2009-03-31 HK HK09103051.1A patent/HK1125103A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE502006009169D1 (en) | NEUE POLYMORPHE FORM VON 5-CHLOR-N-(ä ( 5S )-2-0X0-3-Ä4-( 3-OXO-4-MORPHOLINYL)-PHENYLÜ-1,3-OXAZOLIDIN-5-YLü -METHYL)-2-THIOPHENCARBOXAMID | |
MY138386A (en) | Process for the preparation of a solid, orally administrable pharmaceutical composition | |
BRPI0418405B8 (pt) | processo para preparação de 5-cloro- n -({(5 s )-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida | |
ATE545645T1 (de) | Neue cokristall-verbindung von rivaroxaban und malonsäure | |
WO2007039122A3 (de) | Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung | |
IL210483A0 (en) | Pharmaceutical compositions comprising 5-chlooro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid | |
ZA200802871B (en) | Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide | |
HK1130252A1 (en) | Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders | |
WO2010017948A3 (en) | Pharmaceutical compositions of rivaroxaban with modified release properties | |
MX2009001977A (es) | Derivados profarmacologicos de aminoacilo y medicamentos para el tratamiento de enfermedades tromboembolicas. | |
UA94428C2 (en) | Polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide | |
PH12015501625A1 (en) | Aldehyde derivative of substitute oxazolidinones | |
CU20080051A7 (es) | Nueva forma polimórfica y la forma amorfa de 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida | |
UY28628A1 (es) | Procedimiento para la preparación de una composición farmacéutica sólida administrable oralmente | |
DOP2004001034A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente que comprende 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida en forma hidrofilizada |